OverviewSuggest Edit

Argenx is a clinical-stage biotechnology company developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. It develops the Simple Antibody platform based on the llama immune system to develop antibody-based drugs.
TypePublic
Founded2008
HQGent, BE
Websiteargenx.com

Locations

Argenx is headquartered in
Gent, Belgium

Location Map

Latest Updates

Employees (est.) (Dec 2018)105
Share Price (Feb 2020)$160.2

Argenx Office Locations

Argenx has offices in Gent, Boston, Tokyo and Breda
Gent, BE (HQ)
Technologiepark-Zwijnaarde 30
Tokyo, JP
Oak Minami Azabu Building 11F 3-19-23 Minami Azabu, Minato-ku
Breda, NL
Willemstraat 5
Boston, US
33 Arch Street, 32nd floor Suite 3201
Show all (4)

Argenx Financials and Metrics

Argenx Revenue

Market capitalization (14-Feb-2020)

6.8b

Closing stock price (14-Feb-2020)

160.2
Argenx's current market capitalization is $6.8 b.
Show all financial metrics

Argenx Online and Social Media Presence

Embed Graph

Argenx Frequently Asked Questions

  • When was Argenx founded?

    Argenx was founded in 2008.

  • How many employees does Argenx have?

    Argenx has 105 employees.

  • Who are Argenx competitors?

    Competitors of Argenx include Erydel, Procarta Biosystems and Imcyse.

  • Where is Argenx headquarters?

    Argenx headquarters is located at Technologiepark-Zwijnaarde 30, Gent.

  • Where are Argenx offices?

    Argenx has offices in Gent, Boston, Tokyo and Breda.

  • How many offices does Argenx have?

    Argenx has 4 offices.